Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)

Main Article Content

Gordon Sussman
Jacques Hebert
Wayne Gulliver
Charles Lynde
William H Lang
Olivier Chambenoit
Gretty Deutsch
Frederica DeTakaosy
Lenka Rihakova


omalizumab, urticaria, chronic urticaria


Abstract not available.


Disclosures: Study sponsored by Novartis.


Copyright 2018 SKIN

Most read articles by the same author(s)

1 2 > >>